Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021
4d Pharma PLC (DDDD.L) 4D pharma presents two clinical posters for Live
Avacta Group PLC (AVCT.L) New appointments to Scientific Advisory Board
Avacta announces new appointments to the Scientific Advisory Board of its Therapeutics Division
4d Pharma PLC (DDDD.L) Two MRx0518 presentations accepted for ESMO 2021
4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021
4d Pharma PLC (DDDD.L) $30 Million Credit Facility with Oxford Finance
Leeds, UK, July 29, 2021 – 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived
4d Pharma PLC (DDDD.L) Passing of Chief Financial Officer John Beck
Leeds, UK, July 26, 2021 – 4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived
Avacta Group PLC (AVCT.L) Diagnostics achieves ISO 13485 Certification
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that Avacta Life Sciences’ diagnostics
4d Pharma PLC (DDDD.L) Publication – LBP improves activity of CAR-T
4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T
Avacta Group PLC (AVCT.L) AffiDX Lateral Flow Test Detects Delta Variant
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that a study has shown
4d Pharma PLC (DDDD.L) Conference presentation on LBP Manufacturing
4D pharma to Present at the Microbiome Movement Drug Development Summit
Avacta Group PLC (AVCT.L) Registration of AffiDX Lateral Flow Test in EU
Registration of Avacta’s AffiDX® SARS-CoV-2 Antigen Lateral Flow Test in EU
Avacta Group PLC (AVCT.L) Response to speculation
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, notes speculation regarding the ongoing CE mark submission for
